Published in Cancer on March 01, 2003
Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27
Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer (2009) 1.31
Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol Interv (2008) 1.31
Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed) (2011) 1.12
Anorexia-cachexia and obesity treatment may be two sides of the same coin: role of the TGF-b superfamily cytokine MIC-1/GDF15. Int J Obes (Lond) (2015) 1.08
The translation inhibitor pateamine A prevents cachexia-induced muscle wasting in mice. Nat Commun (2012) 1.05
Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle (2012) 1.05
Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15. J Cachexia Sarcopenia Muscle (2012) 1.02
ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis (2009) 1.02
Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol (2007) 1.00
Biomarkers for cancer cachexia: is there also a genetic component to cachexia? Support Care Cancer (2007) 0.94
Association of interleukin-8 with cachexia from patients with low-third gastric cancer. Comp Funct Genomics (2009) 0.91
Hypogonadism in male cancer patients. J Cachexia Sarcopenia Muscle (2012) 0.85
Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int J Clin Oncol (2009) 0.85
Increased tumor necrosis factor receptor 1 expression in human colorectal adenomas. World J Gastroenterol (2012) 0.85
Serum cytokine profiles in patients with prostate carcinoma. Exp Ther Med (2011) 0.83
Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med (2013) 0.82
Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment. Antioxid Redox Signal (2014) 0.82
Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. J Immunother Cancer (2015) 0.80
Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Res (2013) 0.80
Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. Support Care Cancer (2004) 0.80
Protein calorie malnutrition, nutritional intervention and personalized cancer care. Oncotarget (2017) 0.80
Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? Oncology (Williston Park) (2014) 0.78
Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes. J Control Release (2015) 0.78
Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia - can findings from animal models be translated to humans? BMC Cancer (2016) 0.77
The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting. Semin Cell Dev Biol (2015) 0.77
Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer. Dig Dis Sci (2015) 0.77
New serum biomarkers for prostate cancer diagnosis. Clin Cancer Investig J (2015) 0.76
Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis. Immunology (2016) 0.75
Leptin levels recover normally in healthy older adults after acute diet-induced weight loss. J Nutr Health Aging (2008) 0.75
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med (2007) 2.20
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res (2003) 2.14
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res (2011) 2.10
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2013) 1.95
Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol (2008) 1.91
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.84
In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res (2005) 1.82
Cancer micrometastasis and tumour dormancy. APMIS (2008) 1.78
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol (2009) 1.67
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets (2009) 1.66
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol (2012) 1.65
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
The incidence and success of treatment for severe chronic groin pain after open, transabdominal preperitoneal, and totally extraperitoneal hernia repair. World J Surg (2010) 1.55
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2014) 1.53
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev (2011) 1.51
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res (2006) 1.47
The utility of base deficit and arterial lactate in differentiating major from minor injury in trauma patients with normal vital signs. Resuscitation (2008) 1.43
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res (2009) 1.42
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis (2007) 1.41
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol (2007) 1.41
A multidisciplinary, learner-centered, student-run clinic for the homeless. Fam Med (2003) 1.39
Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37
APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer (2002) 1.35
Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol (2011) 1.33
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate (2003) 1.30
Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis (2008) 1.25
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer (2006) 1.23
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med (2011) 1.23
Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res (2002) 1.19
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget (2013) 1.17
Platelet rich therapies for long bone healing in adults. Cochrane Database Syst Rev (2012) 1.17
Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci (2009) 1.15
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate (2010) 1.14
Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate (2009) 1.14
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol (2013) 1.14
Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem (2009) 1.14
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol (2010) 1.12
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest (2013) 1.10
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate (2008) 1.09
Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res (2004) 1.08
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res (2013) 1.07
Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res (2006) 1.06
Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia (2010) 1.06
Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2004) 1.06
Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One (2013) 1.03
Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia (2006) 1.02
Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget (2013) 1.02
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs (2007) 1.01
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res (2007) 1.01
Metastases of prostate cancer express estrogen receptor-beta. Urology (2004) 1.01
Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res (2007) 1.00
A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol (2002) 0.97
The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate (2010) 0.96
Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Miner Res (2003) 0.95
When prostate cancer meets bone: control by wnts. Cancer Lett (2007) 0.95
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J Clin Oncol (2012) 0.95
Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study. BMC Cancer (2010) 0.94
Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol (2006) 0.93
Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate (2005) 0.93
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol (2009) 0.93
Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res (2004) 0.93
Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Mol Cancer Res (2013) 0.93
Conventional treatments of localized prostate cancer. Urology (2008) 0.92
Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol (2013) 0.92
Discovery and structure-activity relationship of coumarin derivatives as TNF-alpha inhibitors. Bioorg Med Chem Lett (2004) 0.92